Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 2:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 82 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Measurable Residual Disease (MRD) Clear all
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Lymphoma
Interventions
Mosunetuzumab, Ibrutinib, Acalabrutinib, Zanubrutinib, Pirtobrutinib
Drug
Lead sponsor
Inhye Ahn
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced May 22, 2026, 2:49 AM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Acute Myeloid Leukemia
Interventions
MCLA-117 bispecific antibody
Drug
Lead sponsor
Merus B.V.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 5, 2025 · Synced May 22, 2026, 2:49 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Gemtuzumab Ozogamicin, Quality-of-Life Assessment
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced May 22, 2026, 2:49 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Multiple Myeloma, Newly Diagnosed, Multiple Myeloma (MM)
Interventions
Elranatamab, Daratumumab, Lenalidomide, autologous stem cell transplantation
Drug · Procedure
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
19 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
11
States / cities
Birmingham, Alabama • Denver, Colorado • Iowa City, Iowa + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced May 22, 2026, 2:49 AM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Colorectal Cancer, Minimal Residual Disease
Interventions
Fludarabine Phosphate, Cyclophosphamide, Cetuximab, TROP2-CAR-NK Cells, Rimiducid (AP1903), Lymphodepleting Chemotherapy
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced May 22, 2026, 2:49 AM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
GDX012 Suspension for IV Infusion
Biological
Lead sponsor
GammaDelta Therapeutics Limited
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 19, 2022 · Synced May 22, 2026, 2:49 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer, Nsclc, NSCLC Stage IV, Minimal Residual Disease, Non Small Cell Lung Cancer Metastatic
Interventions
Local ablative therapy, Blood collection to assess for ctDNA
Procedure · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
9
States / cities
Hartford, Connecticut • Miami, Florida • Basking Ridge, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced May 22, 2026, 2:49 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
Ofatumumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced May 22, 2026, 2:49 AM EDT
Terminated Phase 4 Interventional Results available
View directory record Official record
Conditions
B-precursor Acute Lymphoblastic Leukemia
Interventions
Blinatumomab, Current Wearable Heatlth Monitoring System (CWHMS)
Drug · Device
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
12
States / cities
Duarte, California • Los Angeles, California • Orange, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 17, 2025 · Synced May 22, 2026, 2:49 AM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
B-Cell Acute Lymphoblastic Leukemia
Interventions
CTL019
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Year to 25 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced May 22, 2026, 2:49 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Daratumumab, Lenalidomide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced May 22, 2026, 2:49 AM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck, Squamous Cell Carcinoma Head and Neck Cancer (HNSCC), Squamous Cell Carcinoma of Skin, Cutaneous Squamous Cell Carcinoma (CSCC)
Interventions
Blood Specimen Collection, Tumor Tissue Collection, Medical Record Review
Procedure · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced May 22, 2026, 2:49 AM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Cutaneous Squamous Cell Carcinoma
Interventions
Blood and Tissue Collection
Diagnostic Test
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced May 22, 2026, 2:49 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Amyloidosis
Interventions
blood collection, bone marrow collection
Other
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 9, 2021 · Synced May 22, 2026, 2:49 AM EDT
Active, not recruiting Phase 2 Interventional Results available
View directory record Official record
Conditions
Hairy Cell Leukemia
Interventions
Pentostatin, Rituximab, Bendamustine, Acetaminophen, Diphenhydramine, Epinephrine, Antihistamines, Corticosteroids, Bronchodilators, Intravenous (IV) Saline
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced May 22, 2026, 2:49 AM EDT
Active, not recruiting No phase listed Observational
View directory record Official record
Conditions
Colorectal Cancer
Interventions
MRD
Device
Lead sponsor
Exact Sciences Corporation
Industry
Eligibility
18 Years and older
Enrollment
1,017 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
28
States / cities
Mission Hills, California • Torrance, California • Gainesville, Florida + 25 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced May 22, 2026, 2:49 AM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions
PRGN-3006 T Cells
Drug
Lead sponsor
Precigen, Inc
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
Tampa, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 7, 2024 · Synced May 22, 2026, 2:49 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Leukemia
Interventions
PEG-IFNá-2a
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 3, 2015 · Synced May 22, 2026, 2:49 AM EDT
Recruiting Early Phase 1 Interventional
View directory record Official record
Conditions
Acute Myeloid Leukemia, Pediatric AML
Interventions
Idarubicin Hydrochloride, Fludarabine, Cytarabine (Ara-C), Venetoclax, Etoposide, Asparaginase Erwinia Chrysanthemi (recombinant), Intrathecal triple, SOC
Drug · Other
Lead sponsor
Joanna Yi
Other
Eligibility
1 Month to 30 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced May 22, 2026, 2:49 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Leukemia
Interventions
Azacitidine (AZA), Tyrosine kinase inhibitor (TKI), Azacitidine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced May 22, 2026, 2:49 AM EDT
Approved For Marketing No phase listed Expanded access
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), FMS-like Tyrosine Kinase-3 (FLT3) Mutations
Interventions
gilteritinib
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
U.S. locations
32
States / cities
Los Angeles, California • Aurora, Colorado • Pembroke Pines, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced May 22, 2026, 2:49 AM EDT
Active, not recruiting No phase listed Observational
View directory record Official record
Conditions
Cancer, Solid Tumor, Non Small Cell Lung Cancer, Colorectal Cancer, Bladder Cancer
Interventions
Personalized Cancer Monitoring (PCM)
Diagnostic Test
Lead sponsor
Invitae Corporation
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Columbus, Indiana • Jacksonville, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 11, 2024 · Synced May 22, 2026, 2:49 AM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
TNBC - Triple-Negative Breast Cancer, Minimal Residual Disease
Interventions
Not listed
Lead sponsor
Personalis Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
422 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
14
States / cities
Tucson, Arizona • Aurora, Colorado • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2025 · Synced May 22, 2026, 2:49 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Cytarabine, Daunorubicin Hydrochloride, Venetoclax
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 59 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
167
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 136 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced May 22, 2026, 2:49 AM EDT